Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate

作者：Barra Sergio; Boveda Serge; Providencia Rui; Sadoul Nicolas; Duehmke Rudolf; Reitan Christian; Borgquist Rasmus; Narayanan Kumar; Hidden Lucet Francoise; Klug Didier; Defaye Pascal; Gras Daniel; Anselme Frederic; Leclercq Christophe; Hermida Jean Sebastien; Deharo Jean Claude; Looi Khang Li; Chow Anthony W; Virdee Munmohan; Fynn Simon; Le Heuzey Jean Yves; Marijon Eloi; Agarwal Sharad

来源：Journal of the American College of Cardiology, 2017, 69(13): 1669-1678.

DOI：10.1016/j.jacc.2017.01.042

• all-cause mortality
• cause of death analysis
• dilated cardiomyopathy
• implantable cardioverter-defibrillator
• ischemic cardiomyopathy
• sudden cardiac death

BACKGROUND Patients with nonischemic dilated cardiomyopathy (DCM) may be at lower risk for ventricular arrhythmias compared with those with ischemic cardiomyopathy (ICM). In addition, DCM has been identified as a predictor of positive response to cardiac resynchronization therapy (CRT).
OBJECTIVES The aim of this study was to investigate the impact of an additional implantable cardioverter-defibrillator over CRT, according to underlying heart disease, in a large study group of primary prevention patients with heart failure.
METHODS This was an observational, multicenter, European cohort study of 5,307 consecutive patients with DCM or ICM, no history of sustained ventricular arrhythmias, who underwent CRT implantation with (n = 4,037) or without (n = 1,270) a defibrillator. Propensity-score and cause-of-death analyses were used to compare outcomes.
RESULTS After a mean follow-up period of 41.4 +/- 29.0 months, patients with ICM had better survival when receiving CRT with a defibrillator compared with those who received CRT without a defibrillator (hazard ratio for mortality adjusted on propensity score and all mortality predictors: 0.76; 95% confidence interval [CI]: 0.62 to 0.92; p = 0.005), whereas in patients with DCM, no such difference was observed (hazard ratio: 0.92; 95% CI: 0.73 to 1.16; p = 0.49). Compared with recipients of defibrillators, the excess mortality in patients who did not receive defibrillators was related to sudden cardiac death in 8.0% among those with ICM but in only 0.4% of those with DCM.
CONCLUSIONS Among patients with heart failure with indications for CRT, those with DCM may not benefit from additional primary prevention implantable cardioverter-defibrillator therapy, as opposed to those with ICM.

• 出版日期2017-4-4